Skip to main content
Premium Trial:

Request an Annual Quote

Illumina and University of Oxford to Sequence 500 Human Genomes to Inform Diagnosis, Treatment


Illumina and researchers at the University of Oxford will jointly sequence 500 human genomes from patients with a variety of diseases in order to help with their diagnosis and treatment, the company said this week.

The project will involve more than 100 diseases and focus primarily on cancer, immunological disorders, and rare Mendelian diseases, all involving genetic mutations that would be difficult to discover using standard genetic tests. The researchers solicited suitable cases that might benefit from whole-genome sequencing from the Oxford clinical community.

Researchers at the Wellcome Trust Centre for Human Genetics in Oxford will sequence 400 genomes on the Illumina HiSeq 2000 platform, while Illumina will sequence 100 genomes at its Little Chesterford site near Cambridge, UK.

The partners have already sequenced the genome of a four-year-old girl who suffers from a life-threatening cranial developmental defect, as well as the genomes of family members, and said that they have identified mutations that will enable them to diagnose the disorder, help them evaluate treatment options, and provide genetic counseling to the family.

"This case demonstrates the great potential of next-generation sequencing technology to elucidate the underlying genetic disorders that are difficult to diagnose," said Peter Donnelly, director of the Wellcome Trust Centre for Human Genetics, in a statement.

The partnership is the second large-scale human genome sequencing agreement in the UK that Illumina has signed in recent weeks. Last week, the company said that Cancer Research UK had selected it to sequence up to 1,500 tumor and normal genomes as part of its contribution to the International Cancer Genome Consortium (CSN 7/27/2011).

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.